Literature DB >> 2305256

Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses.

P Lusso1, F di Marzo Veronese, B Ensoli, G Franchini, C Jemma, S E DeRocco, V S Kalyanaraman, R C Gallo.   

Abstract

In view of the current interest in in vivo murine models for acquired immunodeficiency syndrome (AIDS), the interaction between human immunodeficiency virus type 1 (HIV-1) and endogenous murine leukemia virus (MuLV)-related retroviruses was investigated with a human leukemic T cell line (PF-382x) that acquired xenotropic MuLV (X-MuLV) after in vivo passage in immunosuppressed mice. Despite similar levels of membrane CD4 expression and HIV-1 125I-labeled gp 120 binding, a dramatic acceleration in the time course of HIV-1 infection was observed in PF-382x compared to its X-MuLV-negative counterpart (PF-382). Moreover, PF-382 cells coinfected by X-MuLV and HIV-1 generated a progeny of phenotypically mixed viral particles, enabling HIV-1 to productively infect a panel of CD4- human cells, including B lymphoid cells and purified normal peripheral blood CD4-/CD8+ T lymphocytes. Mixed viral phenotypes were also produced by human CD4+ T cells coinfected with an amphotropic MuLV-related retrovirus (A-MuLV) and HIV-1. These data show that endogenous MuLV acquired by human cells transplanted into mice can significantly interact with HIV-1, thereby inducing important alterations of HIV-1 biological properties.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305256     DOI: 10.1126/science.2305256

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  57 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

Authors:  Michael D Mühlebach; Isabel Schmitt; Stefanie Steidl; Jörn Stitz; Matthias Schweizer; Thomas Blankenstein; Klaus Cichutek; Wolfgang Uckert
Journal:  J Mol Med (Berl)       Date:  2003-10-24       Impact factor: 4.599

3.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 4.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

5.  Foreign glycoproteins can be actively recruited to virus assembly sites during pseudotyping.

Authors:  Rebecca L Jorgenson; Volker M Vogt; Marc C Johnson
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

6.  Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Authors:  Antonio Trabalza; Ioanna Eleftheriadou; Argyro Sgourou; Ting-Yi Liao; Petros Patsali; Heyne Lee; Nicholas D Mazarakis
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

7.  Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Authors:  Yasuhiro Takeuchi; Myra O McClure; Massimo Pizzato
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

8.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.